Affinity binders are the workhorses of assays and methods across the life sciences. From biologics to bioprocessing ligands and research reagents, the requirements for affinity binders vary according to…
This free-to-listen DDW podcast episode is titled “The important role that antibody alternatives play in drug discovery”. It covers an article written for Volume 22, Issue 2 – Spring…
Aptamers are enabling new therapeutics, new diagnostics and the pursuit of new targets. In this on-demand panel discussion experts from industry and academia cover the latest developments in aptamer…
Join experts, including Aptamer Group CTO, Dr David Bunka, for a conversation on recent progress in cancer research, including novel treatments, experimental therapies, and drug development.
Watch as Dr David Bunka, Aptamer Group CTO, and Dr Edgar Goluch, QSM Diagnostics CEO, discuss the application of Optimer binders to the development of novel rapid diagnostics. See how…
Watch as CTO, Dr David Bunka, discusses the use of Optimer® binders as tuneable affinity chromatography ligands to support the development of novel drugs, during the 2021 Biologics Europe…
Watch as Dr David Bunka, Aptamer Group CTO, details how BLI is used within Aptamer Group’s screening and validation processes to identify the best aptamer and Optimer™ reagents, with…
